Flora Peyvandi on Caplacizumab: Which VWF Assays Truly Measure Treatment Effectiveness?
Flora Peyvandi, Professor of Internal Medicine-Hemostasis and Thrombosis Unit, University of Milan, former President of ISTH, shared on X:
“The VWF : GPIbM and VWF:RCo appear the most suitable assays for monitoring VWF activity in iTTP patients treatment with caplacizumab. The VWF:GPIbR have a limited ability to detect caplacizumab’s inhibition. The VWF:Ab assay is unsuitable for this purpose ”
Title: Evaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
Authors: Paola Colpani, Luciano Baronciani, Ilaria Mancini, Cristina Novembrino, Anna Lecchi, Giovanna Cozzi, Pasqualina De Leo, Massimo Boscolo Anzoletti, Silvia La Marca, Marco Boscarino, Maria Teresa Pagliari, Andrea Artoni, Flora Peyvandi
Read the full article here.
Stay updated with Hemostasis Today.
-
Oct 23, 2026, 17:45Lucy Brook: Had the Privilege of Attending the Blood 2026 Conference with New Zealand Blood Service
-
Oct 23, 2026, 16:05Platelet Secretion Defects and Their Role in the Diagnosis of Bleeding Disorders
-
Oct 23, 2026, 16:00Hemophilia Alliance team in New Orleans at the ATHN Data Summit
-
Oct 23, 2026, 15:49Brian Sapp: Why Exact Calf Vein Naming Is Critical for DVT Diagnosis?
-
Oct 23, 2026, 15:33Smitirupa Mishra: A Systematic Approach to Bone Marrow Examination
-
Oct 23, 2026, 15:29José Antonio García Erce: Preoperative Anemia Emerges as a Modifiable Surgical Risk in New POWER Study
-
Oct 23, 2026, 15:13Reza Shojaei: Manufactured Red Blood Cells vs Blood Donation
-
Oct 23, 2026, 14:29Jean Jacques Kiladjian: International Scientific Exchange at IHCAMS in Tianjin
-
Oct 23, 2026, 14:11Aravind Palraj: The Prolonged aPTT Puzzle in SLE